Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
New Strategies for Treatment-Resistant Depression
Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel mechanisms of action.
FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved standalone treatment for this condition.
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
New Spravato Indication Offers Greater Flexibility and Personalization for Patients with Treatment-Resistant Depression
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression.
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
FDA approves antidepressant nasal spray | Morning in America
The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may help those suffering from depression.
News Nation on MSN
19h
Advocates push for more access to psychedelic treatment in Texas
Over the last decade, the use of psychedelic substances has evolved from taboo to be considered by many a legitimate ...
Daily Camera
15h
Boulder Community Health now offering ketamine therapy, other therapies for treatment-resistant conditions
Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
All aboard feared dead
Los Angeles wildfire updates
Agency halts events
Signs education orders
Victims of DC plane crash
FDA upgrades recall
Ex-FDNY chief pleads guilty
'The Voice' alum dies at 44
Senate confirmation hearing
Gun trafficking indictments
Wildfire erupts in NC
Lawsuit to keep records
Senate confirmation hearing
Presidential historian dies
First spacewalk together
DOJ weighs dropping case?
Pushes for earlier trial
Bird flu 'widespread' in MA
Zeldin confirmed by Senate
Jury weighs charges
In talks to invest in OpenAI
Witkoff meets Netanyahu
Fall behind in reading
Agrees to settle Trump suit
Hamas frees more hostages
Plans job, output cuts in US
Syria’s transitional pres
US economy grew 2.3%
Ebola outbreak in Uganda
Related topics
Nasal spray
Food and Drug Administration
Johnson & Johnson
Feedback